Erratum to “Hypertrophic Cardiomyopathy: Is a ‘Cure’ Coming … Or Is It Already Here?”

American Journal of Medicine, 133 (2020):8:886-888.
Published:January 05, 2021DOI:
      The publisher regrets that the figure in the published version of this paper contained incorrect information. The two green boxes in the second row contained incorrect labels: in the darker green box above the words “Surgical Myectomy”, the wording should have read “Symptomatic Heart Failure: Obstructive”. The pale green box with arrow leading to “Drugs” should have read “Symptomatic Heart Failure: Nonobstructive”. This is a very important clinical designation.
      The publisher confirms that the figure was submitted correctly by the authors; we would like to apologize for any inconvenience or confusion caused by this error.
      See below the correct figure and legend as provided by the authors.
      Unlabelled image
      FigureContemporary management strategies associated with clinical benefit for most patients with hypertrophic cardiomyopathy. ASA = alcohol septal ablation; ICD = implantable cardioverter/defibrillator.

      Linked Article

      • Hypertrophic Cardiomyopathy: Is a ‘Cure’ Coming . . . Or Is It Already Here?
        The American Journal of MedicineVol. 133Issue 8
        • Preview
          Over its 60-year history, a consistent theme attached to hypertrophic cardiomyopathy (HCM) has been controversy concerning its prevalence, clinical course, and expectations for treatment benefit.1 Once regarded as rare and ominous, HCM is now recognized as a common genetic disease with worldwide distribution, broad spectrum, and clinical outcome transformed over the last several years by the introduction of management strategies that favorably alter its natural history and provide a high level of care for the vast majority of patients.
        • Full-Text
        • PDF